Perhaps the most exciting and promising news in diabetic cardiomyopathy and HF more generally, is the recent advent of the SGLT2 inhibitors as a therapy for HFpEF.350 Initially promoted solely as a class of antidiabetic drugs, SGLT2 inhibitors improve glycaemic control, reduce body mass, and lower blood pressure.351 However, over several clinical trials, the SGLT2 inhibitors dapagliflozin,352 empagliflozin,353 canagliflozin,354 and others, were shown to prevent HF and reduce hospitalization and cardiovascular death in T2DM patients with HFrEF. Here, SLC5A2 is linked to type 2 diabetes mellitus.